Literature DB >> 19308306

Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities.

Helen Tremlett1, Yinshan Zhao, Virginia Devonshire.   

Abstract

BACKGROUND: Similarities in the onset age of progression in secondary-progressive (SP) and primary-progressive multiple sclerosis (PPMS) have been previously reported. However, with longer follow-up, more relapsing-remitting (RRMS) patients reach SPMS, such that the baseline characteristics, including age at progression may shift. We aimed to examine how this phenomenon impacts on demographic and clinical comparisons made between PP and SPMS. METHODS AND
RESULTS: Patients with definite MS, onset by July 1988 and > or = 1 Expanded Disability Status Scale (EDSS) score were selected from the British Columbia-wide MS database (n = 2837). Of these, 353 (12.4 %) had PPMS and 1445/2484 (58.2 %) of the RRMS population reached SPMS at study close (July 2003). Females predominated in the SPMS population regardless of follow-up time (p < or = 0.032). From Kaplan-Meier analysis (all RR, SP and PP patients considered), the estimated median onset age of progression was greater in SPMS (49.0 years; 95 % CI: 48.3-49.7) than PPMS (41.0 years; 95 % CI: 39.7-42.4), p < 0.0005. If the RR patients (who had not developed SPMS) were excluded, median age of onset of SPMS was still greater (43.1 years (95 % CI: 42.3-43.9, p < 0.0005).
CONCLUSIONS: Although there were some similarities between SPMS and PPMS, the former had a later onset age in our British Columbian MS cohort.

Entities:  

Mesh:

Year:  2009        PMID: 19308306     DOI: 10.1007/s00415-009-0039-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  Bayesian analysis: what does it add to studies of the natural history of MS?

Authors:  B G Weinshenker
Journal:  J Neurol Sci       Date:  2001-08-15       Impact factor: 3.181

2.  Progression in multiple sclerosis: further evidence of an age dependent process.

Authors:  Marcus Koch; Jop Mostert; Dorothea Heersema; Jacques De Keyser
Journal:  J Neurol Sci       Date:  2007-02-27       Impact factor: 3.181

3.  Disability progression in multiple sclerosis is slower than previously reported.

Authors:  Helen Tremlett; Donald Paty; Virginia Devonshire
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

Review 4.  Secondary progressive multiple sclerosis: current knowledge and future challenges.

Authors:  Marco Rovaris; Christian Confavreux; Roberto Furlan; Ludwig Kappos; Giancarlo Comi; Massimo Filippi
Journal:  Lancet Neurol       Date:  2006-04       Impact factor: 44.182

5.  Some aspects of the natural history of disseminated sclerosis.

Authors:  D McALPINE; N COMPSTON
Journal:  Q J Med       Date:  1952-04

6.  Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study.

Authors:  J M Minderhoud; J H van der Hoeven; A J Prange
Journal:  Acta Neurol Scand       Date:  1988-07       Impact factor: 3.209

7.  Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

Authors:  B Runmarker; O Andersen
Journal:  Brain       Date:  1993-02       Impact factor: 13.501

8.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

9.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

10.  Cerebral microbleeds are common in ischemic stroke but rare in TIA.

Authors:  D J Werring; L J Coward; N A Losseff; H R Jäger; M M Brown
Journal:  Neurology       Date:  2005-12-27       Impact factor: 9.910

View more
  21 in total

1.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

Review 2.  A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.

Authors:  Hernan Inojosa; Undine Proschmann; Katja Akgün; Tjalf Ziemssen
Journal:  J Neurol       Date:  2019-07-30       Impact factor: 4.849

3.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

4.  Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.

Authors:  Luis Hernandez; Malinda O'Donnell; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

5.  Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Authors:  Melih Tutuncu; Junger Tang; Nuhad Abou Zeid; Nilufer Kale; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; Sean J Pittock; Istvan Pirko; B Mark Keegan; Claudia F Lucchinetti; John H Noseworthy; Moses Rodriguez; Brian G Weinshenker; Orhun H Kantarci
Journal:  Mult Scler       Date:  2012-06-26       Impact factor: 6.312

Review 6.  Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.

Authors:  Jeffrey M Gelfand; Bruce A C Cree; Stephen L Hauser
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

7.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

8.  Evidence for a two-stage disability progression in multiple sclerosis.

Authors:  Emmanuelle Leray; Jacqueline Yaouanq; Emmanuelle Le Page; Marc Coustans; David Laplaud; Joël Oger; Gilles Edan
Journal:  Brain       Date:  2010-04-27       Impact factor: 13.501

Review 9.  Advances in multiple sclerosis research in 2009.

Authors:  Stefan Nessler; Wolfgang Brück
Journal:  J Neurol       Date:  2010-08-06       Impact factor: 4.849

Review 10.  Sex differences in autoimmune disorders of the central nervous system.

Authors:  Stefan M Gold; Anne Willing; Frank Leypoldt; Friedemann Paul; Manuel A Friese
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.